| 证券代码 | ADMS.O |
| 证券名称 | Adamas Pharmaceuticals Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-04-10 |
| 首发价格(元) | 16 USD |
| 首发数量(股) | 3000000 |
| 首发募资额(元) | 48,000,000.00 USD |
| 首发主承销商 | Credit Suisse Securities (USA) LLC,Piper Jaffray & Co. |
| 货币单位 | USD |
| 公司名称 | Adamas Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 1900 Powell Street, Suite 750, Emeryville, California, USA |
| 成立日期 | 2000-11-15 |
| 董事会主席 | David L. Mahoney |
| 公司属地 | United States 美国 |
| 公司网址 | www.adamaspharma.com |
| 电话 | +1 (510) 450-3500 |
| 传真 | +1 (510) 428-0519 |
| 公司简介 | Adamas Pharmaceuticals, Inc. is a pharmaceutical company that develops new medicines to improve the daily lives of those affected by chronic neurologic disorders. Approximately 36 million people in the United States suffer from conditions such as Alzheimer’s disease, Parkinson’s disease (PD), multiple sclerosis and epilepsy. Symptoms associated with these disorders can be treated sub-optimally due to tolerability issues, which may limit the amount of drug that is present when patients need relief. |